Patent ruling on Lilly's Alimta lung-cancer drug expected in 2014

(Reuters) - A high-stakes decision on whether to extend U.S. marketing exclusivity of Eli Lilly and Co's blockbuster Alimta lung cancer drug is not expected until next year, following a two-week trial in Indianapolis federal court.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/raUPIvB3okA/story01.htm

phlebotomy courses in nj phlebotomy training in illinois phlebotomy training in brooklyn